
|Videos|January 25, 2022
Dr. Albala on the recent CMS change for Rezum water vapor therapy
Author(s)Urology Times staff
“I think this really now suggests that Rezum is a financially viable procedure across these different treatment settings…the reimbursement now is really quite favorable,” says David M. Albala, MD.
Advertisement
In this video, David M. Albala, MD, discusses the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy. This new change allows for more financial coverage for patients with benign prostatic hyperplasia (BPH) who seek this treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves label changes for first batch of menopausal hormone therapy products
2
Urologist explains science behind HA penile injections
3
Dual AR blockade shows promise for treatment-naïve mHSPC
4
Pearls & Perspectives: Expanding Options in Male Incontinence, with Laura Horodyski, MD
5






